1. Signaling Pathways
  2. MAPK/ERK Pathway
  3. Raf
  4. Raf Inhibitors

Raf Inhibitors

BRaf

c-Raf

Raf

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.

Raf Inhibitors
Product Name BRaf c-Raf Raf Purity
Sorafenib
Braf, IC50: 22 nM
BrafV599E, IC50: 38 nM
Raf-1, IC50: 6 nM
  99.92%
Dabrafenib
BRafV600E, IC50: 0.6 nM
CRAF, IC50: 5 nM
  99.91%
Vemurafenib
B-RafV600E, IC50: 31 nM
c-Raf-1, IC50: 48 nM
  99.83%
Regorafenib
Braf, IC50: 28 nM
BRafV600E, IC50: 19 nM
Raf-1, IC50: 2.5 nM
  99.65%
Doramapimod
B-Raf, IC50: 83.4 nM
    99.98%
B-Raf IN 11
B-RafV600E, IC50: 76 nM
BRAFWT, IC50: 238 nM
   
Sorafenib Tosylate
Braf, IC50: 22 nM
BrafV599E, IC50: 38 nM
Raf-1, IC50: 6 nM
  99.75%
Belvarafenib
BRafV600E, IC50: 7 nM
B-Raf, IC50: 56 nM
CRAF, IC50: 5 nM
  98.05%
PLX-4720
B-RafV600E, IC50: 13 nM
B-Raf, IC50: 160 nM
    99.91%
AZ 628
B-Raf, IC50: 105 nM
B-RafV600E, IC50: 34 nM
c-Raf-1, IC50: 29 nM
  99.85%
GDC-0879
B-Raf, IC50: 0.13 nM
    99.57%
LY3009120
BRafV600E, IC50: 5.8 nM
Braf, IC50: 9.1 nM
CRAF, IC50: 15 nM
  98.97%
SB-590885
B-Raf, Ki: 0.16 nM
c-Raf, Ki: 1.72 nM
  99.56%
Avutometinib
BRafV600E, IC50: 8.2 nM
Braf, IC50: 190 nM
CRAF, IC50: 56 nM
  98.99%
GW 5074  
c-Raf, IC50: 9 nM
  99.49%
Dabrafenib Mesylate
BRafV600E, IC50: 0.6 nM
CRAF, IC50: 5 nM
  99.95%
Tovorafenib    
RAF
99.89%
LXH254
Braf, IC50: 0.21 nM
CRAF, IC50: 0.072 nM
  99.95%
Lifirafenib
BRafV600E, IC50: 23 nM
    98.73%
RAF265    
RAF
99.90%
RAF709
Braf, IC50: 0.4 nM
CRAF, IC50: 0.5 nM
  98.87%
BI-882370
Braf, IC50: 0.6 nM
BRafV600E, IC50: 0.4 nM
c-Raf, IC50: 0.8 nM
  99.16%
Regorafenib Hydrochloride
Braf, IC50: 28 nM
BRafV600E, IC50: 19 nM
Raf-1, IC50: 2.5 nM
  99.58%
ZM 336372  
c-Raf, IC50: 0.07 μM (0.1 mM ATP)
  98.42%
AD80    
RAF
99.85%
Agerafenib
Braf, Kd: 36 nM
BRafV600E, Kd: 14 nM
CRAF, Kd: 39 nM
  99.63%
Rineterkib    
RAF
99.21%
Regorafenib monohydrate
Braf, IC50: 28 nM
BRafV600E, IC50: 19 nM
Raf-1, IC50: 2.5 nM
  99.96%
CCT196969
BRafV600E, IC50: 0.04 μM
Braf, IC50: 0.1 μM
CRAF, IC50: 0.01 μM
  99.63%
HG6-64-1
B-RafV600E, IC50: 0.09 μM (in Ba/F3 cells)
    ≥98.0%
MCP110    
RAF
99.82%
PLX7904
BRafV600E, IC50: 5 nM (in mutant RAS expressing cells)
    98.62%
PROTAC B-Raf degrader 1
B-Raf
    99.78%
B-Raf IN 1
B-Raf, IC50: 24 nM
    98.66%
BRAF inhibitor
B-Raf
    99.22%
Raf inhibitor 1
B-Raf, Ki: 1 nM
B-RafV600E, Ki: 1 nM
c-Raf, Ki: 0.3 nM
  98.11%
L-779450
B-Raf, Kd: 2.4 nM
    98.88%
RAS/RAS-RAF-IN-1    
RAF
98.41%
LUT014
B-Raf, IC50: 11.7 nM
   
AZ304
BRafV600E, IC50: 38 nM
BRAFWT, IC50: 79 nM
CRAF, IC50: 68 nM
  99.96%
GNE-9815
Braf, Ki: 0.19 nM
CRAF, Ki: 0.062 nM
  98.02%
KG5
B-Raf
c-Raf
  99.79%
Tinlorafenib
BRafV600E, IC50: 4.25 nM
    98.20%
B-Raf IN 2
BRafV600E
    99.27%
Regorafenib mesylate
BRafV600E, IC50: 19 ± 6 nM
B-Raf, IC50: 28 ± 10 nM
Raf-1, IC50: 2.5 ± 0.6 nM
 
B-Raf IN 10
Braf, IC50: 50-100 nM
BRAF-V600E, IC50: < 50 nM
    99.15%
PROTAC BRAF-V600E degrader-1
BRAF-V600E, Kd: 2 nM
Braf, Kd: 2.4 nM
    98.02%
(Z)-GW 5074  
c-Raf
 
RAF mutant-IN-1
B-RafV600E, IC50: 30 nM
BRAFWT, IC50: 392 nM
C-RAF 340D/Y341D, IC50: 21 nM
 
EGFR/BRAF-IN-1
BRafV600E, IC50: 45 nM
   
PF-04880594
Braf
CRAF
 
VEGFR-2/BRAF-IN-2
BRafV600E, IC50: 0.089 μM
BRAFWT, IC50: 0.071 μM
   
B-Raf IN 9
B-Raf, IC50: 24.97 ± 0. nM
   
VEGFR-2/BRAF-IN-1
BRafV600E, IC50: 0.063 μM
BRAFWT, IC50: 0.005 μM
   
B-Raf IN 7
B-Raf, IC50: 110.23 ± 0 nM
   
SHR902275
BRafV600E, IC50: 5.7 nM
BRAFWT, IC50: 10 nM
c-Raf, IC50: 1.6 nM
 
ML786 dihydrochloride    
RAF, IC50: 2.1 nM
Takeda-6D
Braf, IC50: 7.0 nM
   
RAF-IN-1
BRafV600E, IC50: 29.4 nM
BRAFWT, IC50: 36 nM
c-Raf, IC50: 3.8 nM
 
CCT241161
Braf, IC50: 30 nM
BRafV600E, IC50: 15 nM
CRAF, IC50: 6 nM
 
B-Raf IN 8
B-Raf, IC50: 70.65 ± 0. nM
   
Agerafenib hydrochloride
BRafV600E, Kd: 14 nM
Braf, Kd: 36 nM
CRAF, Kd: 39 nM
 
Raf inhibitor 1 dihydrochloride
B-Raf, Ki: 1 nM
B-RafV600E, Ki: 1 nM
c-Raf, Ki: 0.3 nM